SuperworthMapLight Therapeutics MPLT
- Market cap
- $369.6M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −47.4%
Charts
Financials
| Income statement | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| R&D | $16.8M | $20.7M | $19.8M | $26.8M | $27.1M+61% | $64.6M+212% | $53.7M+171% | $53.4M+99% |
| SG&A | $4.1M | $2.1M | $3.8M | $3.8M | $4.4M+8% | $18.8M+809% | $10.8M+188% | $10.1M+165% |
| −$20.9M | −$22.8M | −$23.5M | −$30.7M | −$31.5M+51% | −$83.4M+266% | −$64.5M+174% | −$63.5M+107% | |
| Net income | −$19M | −$21.2M | −$22.3M | −$29.8M | −$29.4M+55% | −$79.5M+275% | −$60.7M+172% | −$60.2M+102% |
| −$25.08 | −$27.95 | −$29.33 | −$39.11 | −$37.18+48% | n/a | −$1.34−95% | −$1.32−97% | |
| 758.2K | 759.5K | 761.6K | 763K | 791.1K+4% | n/a | 45.3M+5845% | 45.4M+5854% |
EPS, diluted: Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest MapLight Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MPLTMapLight Therapeutics | $369.6M | n/m | n/a | n/m | n/m | n/m | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| Peer median | $597.2M | 11.5× | 13.6× | 1.5× | +11% | 11.6% |
More on MapLight Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .